Apixaban Outperforms Warfarin in Reducing Blood Clot Complications and Hospitalization Stays for Older Patients

New Medicare study shows apixaban reduces bleeding risks and keeps older patients home longer compared to warfarin and rivaroxaban.

By: AXL Media

Published: Apr 28, 2026, 6:16 AM EDT

Source: Information for this report was sourced from EurekAlert!

Superior Outcomes for Apixaban in Geriatric Thromboembolism Care

A comprehensive analysis of Medicare data has revealed that the anticoagulant apixaban, commercially known as Eliquis, offers superior clinical results for older adults recovering from serious blood clots. Researchers from the Hinda and Arthur Marcus Institute for Aging Research found that patients treated with this medication faced fewer major complications than those prescribed warfarin. This study is particularly significant as it focuses on venous thromboembolism, a condition encompassing deep vein thrombosis and pulmonary embolism, which often leads to high mortality rates in the elderly.

Evaluating Treatment Impact Across Frailty Spectrums

The research team analyzed claims data from 2015 to 2019, specifically investigating how different oral anticoagulants affect both frail and non-frail populations. While clinical trials often underrepresent frail individuals, this study confirmed that apixaban maintained its effectiveness and safety benefits across varying levels of physical resilience. According to lead author Chanmi Park, MD, MPH, these findings suggest that the medication provides a favorable balance of safety and efficacy for a demographic that often faces high risks of bleeding and medication sensitivity.

Measuring the Value of Home Time for Older Adults

Beyond traditional clinical markers, the study utilized "home time" as a primary metric for success, measuring the number of days patients avoided hospitals, emergency departments, and skilled nursing facilities. The results indicated that apixaban users experienced significantly fewer days of lost home time compared to those on warfarin. This patient-centered outcome is viewed as a critical indicator of independence and quality of life for seniors, who often prioritize remaining in their own residences over prolonged stays in rehabilitation centers or nursing homes.